News 2024-06-06
Porton will be Participating in Biotech Outsourcing Strategies Events this June
As the global market for biopharmaceutical research outsourcing continues to flourish, the annual BOS Basel Conference has once again drawn worldwide attention. Since its inception in 2006, the Biotech Outsourcing Strategies (BOS) Events has become a barometer for the research outsourcing industry in Europe and globally. The organizers invite industry experts, business leaders, and scholars to explore key issues in biotech outsourcing, share successful experiences, and establish and strengthen collaborative relationships through a series of keynote speeches, specialized discussions, and roundtable forums.
BOS Basel 2024 is set to kick off in this June. This year's event will continue to focus on the outsourcing of CMC (Chemistry, Manufacturing, and Controls) for small molecules and biologics, with special attention to outsourcing developments in novel therapeutic areas (New Drug Modalities).
At this year's conference, Porton will showcase its end-to-end global CDMO service capabilities and the differentiated advantages it offers to customers. Whether its new drug development, process transfer optimization, or commercial manufacturing, Porton is committed to actively listening to customer needs and providing efficient, precise CDMO solutions.
On May 22, 2024, Porton PharmaTech celebrated the grand opening of its state-of-the-art research and development laboratories for active pharmaceutical ingredients (APIs) and small molecules in Mengeš. This event marks another significant milestone in Porton's globalization journey, following the acquisition of the US-based CRO, J-STAR Research Inc., in 2017. Globalization remains our top strategic priority at Porton, as we strive to establish R&D and manufacturing footprints in the United States and Europe. This expansion is designed to meet the growing demands of our global clients for enhanced supply chain security, high-quality, innovative, and reliable services.
Furthermore, this BOS Basel will continue the tradition of previous events by featuring four core activities: Partnering; Exhibition, Informal Networking and more. Porton will actively participate in these segments, sharing experiences, building connections, and fostering collaborations with global peers. We look forward to gathering with industry colleagues in the beautiful city of Basel to witness the brilliant future of the biotech outsourcing field together!
For business meeting appointments,
please contact: business@portonpharma.com.
Others
More
News 2025-03-21
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
News 2025-03-19
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
